Stereotactic Radiosurgery and Stereotactic Radiotherapy - Intracranial (All Ages) Quality Dashboard 2020/21

NHS England

															Reporting Periods			
Indicator Reference Number	Domain	Theme	Measure	Rationale	Name of Indicator / Description	Numerator	Denominator	Period Type	Frequency	Data Source Numerator	Data Source Denominator	Target	Interpretation Guidance	Notes	Q1	Q2	Q3	Q4
ST01a	Domain 1: Preventing people from dying prematurely	Outcome measure	Activity levels - Tier 1 and 2	This indicator is to measure the number of Tier 1 and Tier 2 patients treated with SRS/SRT (per delivery site and treatment platform) as per the service specification: Stereotactic Radiosurgery and Stereotactic Radiotherapy (Intracranial) - D05/S/a	Number of Tier 1 and 2 patients treated with SRS/SRT	Total number of Tier 1 and Tier 2 patients treated with SRS/SRT in the reporting period	N/A	1 Year Rolling	Quarterly	Provider submitted data	N/A	>100 per year	Neutral	Include: any patients treated whether as initial treatment or as 'retreatment'. If a patient received more than 1 treatment in reporting period count as separate. The data required is per delivery site and treatment platform.	Jul 19 - Jun 20	Oct 19 - Sep 20	Jan 20 - Dec 20	Apr 20 - Mar 21
ST01b	Domain 1: Preventing people from dying prematurely	Outcome measure	Activity levels - Tier 3 and 4	This indicator is to measure the number of Tier 3 and Tier 4 patients treated with SRS/SRT (per delivery site and treatment platform) as per the Service Specification: Stereotactic Radiosurgery and Stereotactic Radiotherapy (Intracranial) - D05/S/a	Number of Tier 3 and 4 patients treated with SRS/SRT	Total number of Tier 3 and Tier 4 patients treated with SRS/SRT in the reporting period	N/A	1 Year Rolling	Quarterly	Provider submitted data	N/A	N/A	Neutral	Include: any patients treated whether as initial treatment or as 'retreatment'. If a patient received more than 1 treatment in reporting period count as separate. The data required is per delivery site and treatment platform.	Jul 19 - Jun 20	Oct 19 - Sep 20	Jan 20 - Dec 20	Apr 20 - Mar 21
ST01c	Domain 1: Preventing people from dying prematurely	Outcome measure	Activity levels - paediatric oncology	This indicator is to measure the number of paediatric oncology patients treated with SRS/SRT (per delivery site and treatment platform) as per the Service Specification: Stereotactic Radiosurgery and Stereotactic Radiotherapy (Intracranial) - D05/S/a	Number of paediatric oncology patients treated with SRS/SRT	Total number of paediatric oncology patients treated with SRS/SRT in the reporting period	N/A	1 Year Rolling	Quarterly	Provider submitted data	N/A	N/A	Neutral	Include: any patients treated whether as initial treatment or as 'retreatment'. If a patient received more than 1 treatment in reporting period count as separate. Paediatric oncology patients aged 0 to 15 years, up to their 16th birthday. The data required is per delivery site and treatment platform.	Jul 19 - Jun 20	Oct 19 - Sep 20	Jan 20 - Dec 20	Apr 20 - Mar 21
ST01d	Domain 1: Preventing people from dying prematurely	Outcome measure	Activity levels - TYA	This indicator is to measure the number of Teenagers & Young Adults (TYA) treated with SRS/SRT (per delivery site and treatment platform) as per the service specification: Stereotactic Radiosurgery and Stereotactic Radiotherapy (Intracranial) - D05/S/a	Number of Teenagers & Young Adults (TYA) patients treated with SRS/SRT	Total number of TYA patients treated with SRS/SRT in the reporting period	N/A	1 Year Rolling	Quarterly	Provider submitted data	N/A	N/A	Neutral	Include: Any patients treated whether as initial treatment or as 'retreatment'. If a patient received more than 1 treatment in reporting period count as separate. TYA patients aged from 16 to the end of their 24th year. The data required is per delivery site and treatment platform.	Jul 19 - Jun 20	Oct 19 - Sep 20	Jan 20 - Dec 20	Apr 20 - Mar 21
ST02	Domain 1: Preventing people from dying prematurely	Process measure	Communicating MDT outcomes	Within 2 working days of the definitive management plan being established, the diagnosis and management plan should be communicated to the referring Consultant/MDT and the General Practitioner (GP)	Proportion of patients whose outcome has been communicated to the referring Consultant/MDT and the General Practitioner (GP) within 2 working days of the SRS/SRT MDT meeting	Of those in the denominator, the number of patients whose outcome has been communicated to the referring Consultant/MDT the GP within 2 working days of the SRS/SRT MDT meeting	Total number of Tier 1, Tier 2, Tier 3 and Tier 4 patients discussed at the SRS/SRT MDT in the reporting period	Quarterly	Quarterly	Provider submitted data	Provider submitted data	N/A	Higher is better	The data required is per delivery site and treatment platform.	Apr 20 - Jun 20	Jul 20 - Sep 20	Oct 20 - Dec 20	Jan 21 - Mar 21
ST03	Domain 1: Preventing people from dying prematurely	Process measure	Clinical review - malignant disease	Patients with malignant disease for SRS/SRT should have a clinical review within 1 week of the Neurosciences (Neuro-oncology) MDT meeting as per the service specification: Stereotactic Radiosurgery and Stereotactic Radiotherapy (Intracranial) - D05/S/a	Proportion of patients with malignant disease for SRS/SRT that received a clinical review within 1 week of the Neurosciences (Neuro-oncology) MDT meeting	Of those in the denominator, the number of patients who received a clinical review within 1 week of the Neurosciences (Neuro-oncology) MDT meeting	Total number of patients with malignant disease discussed at the Neurosciences (Neuro-oncology) MDT meeting and recommended as to be considered as a candidate for SRS/SRT treatment in the reporting period	Quarterly	Quarterly	Provider submitted data	Provider submitted data	N/A	Higher is better	Time to clinical review:1 week from the date of the Neurosciences (Neuro-oncology) MDT meeting to the date of the clinical review. The data required is per delivery site and treatment platform.	Apr 20 - Jun 20	Jul 20 - Sep 20	Oct 20 - Dec 20	Jan 21 - Mar 21
ST04	Domain 1: Preventing people from dying prematurely	Process measure	Treatment delivery - malignant disease	For patients with malignant disease, providers should ensure SRS/SRT treatment is delivered within 2 weeks of the decision to treat (in clinic), as per the service specification: Stereotactic Radiosurgery and Stereotactic Radiotherapy (Intracranial) - D05/S/a	Proportion of patients with malignant disease with SRS/SRT treatment delivered within 2 weeks of the decision to treat (in clinic)	Of those in the denominator, the number of patients whose treatment was delivered within 2 weeks of the decision to treat (in clinic)	Total number of patients with malignant disease treated with SRS/SRT in the reporting period	Quarterly	Quarterly	Provider submitted data	Provider submitted data	N/A	Higher is better	Time to treatment: 2 weeks from the date that the decision to treat was agreed with the patient in clinic to the date of treatment. The data required is per delivery site and treatment platform.	Apr 20 - Jun 20	Jul 20 - Sep 20	Oct 20 - Dec 20	Jan 21 - Mar 21
ST05	Domain 1: Preventing people from dying prematurely	Clinical outcome measure	Mortality	This indicator is to measure the proportion of patients that died within 30 days following SRS/SRT treatment	Mortality within 30 days following SRS/SRT treatment	Of those in the denominator, the number of patients who died within 30 days following SRS/SRT treatment	Total number of patients treated with SRS/SRT in the reporting period	1 Year Rolling	Quarterly	Provider submitted data	Provider submitted data	N/A	Lower is better	The data required is per delivery site and treatment platform. This mortality data is not standardised.	Jul 19 - Jun 20	Oct 19 - Sep 20	Jan 20 - Dec 20	Apr 20 - Mar 21

Stereotactic Radiosurgery and Stereotactic Radiotherapy - Intracranial (All Ages) Quality Dashboard 2020/21

NHS England

															Reporting Periods			
Indicator Reference Number	Domain	Theme	Measure	Rationale	Name of Indicator / Description	Numerator	Denominator	Period Type	Frequency	Data Source Numerator	Data Source Denominator	Target	Interpretation Guidance	Notes	Q1	Q2	Q3	Q4
ST06	Domain 1: Preventing people from dying prematurely	Process measure	Performance Status	To consider SRS/SRT treatment, patients with malignant disease should have a Karnofsky Performance Status (KPS) ≥ 70. This indicator is to identify the proportion and number of patients with malignant disease being treated with SRS/SRT with a Karnofsky performance status (KPS) <70	Proportion of patients with malignant disease treated with SRS/SRT with a Karnofsky Performance Status (KPS) <70	Of those in the denominator, the number of patients with a performance status KPS <70	Total number of patients with malignant disease treated with SRS/SRT in the reporting period	Quarterly	Quarterly	Provider submitted data	Provider submitted data	N/A	Lower is better	The data required is per delivery site and treatment platform.	Apr 19 - Jun 19	Jul 20 - Sep 20	Oct 20 - Dec 20	Jan 21 - Mar 21
ST07	Domain 1: Preventing people from dying prematurely	Clinical outcome measure	Malignant Disease - Complications of treatment	This indicator is to measure the proportion of patients with malignant disease that develop a permanent neurological deficit within 6 months of SRS/SRT treatment	Proportion of patients with malignant disease that developed a permanent neurological deficit within 6 months of SRS/SRT treatment	Of those in the denominator, the number of patients that developed a permanent neurological deficit within 6 months of SRS/SRT treatment	Total number of patients with malignant disease treated with SRS/SRT in the reporting period	Annual	Annual	Provider submitted data	Provider submitted data	N/A	Lower is better	The data required is per delivery site and treatment platform.				Oct 19 - Sep 20
ST08	Domain 1: Preventing people from dying prematurely	Clinical outcome measure	Cerebral metastases - requiring retreatment or alternative treatment	Indicator to measure where retreatment or alternative treatment has been required following SRS/SRT treament. This indicator measures the proportion of patients with cerebral metastases treated with SRS/SRT and requiring retreatment or alternative surgical treatment on the same lesion within 12 months	Proportion of patients with cerebral metastases who require retreatment or alternative surgical treatment on the same lesion within 12 months of SRS/SRT treatment	Of those in the denominator, the number of patients that required retreatment or alternative surgical treatment on the same lesion, within 12 months	Total number of patients with cerebral metastases treated with SRS/SRT in the reporting period	Annual	Annual	Provider submitted data	Provider submitted data	N/A	Lower is better	The data required is per delivery site and treatment platform.				Apr 19 - Mar 20
ST09	Domain 2: Enhancing the quality of life of people with long-term conditions	Clinical outcome measure	Meningioma control - steroids required	This indicator is to measure steriod use and where patients treated have required a course of steroids during 6 months since treatment for symptomatic oedema following SRS/SRT treatment	Proportion of patients with meningioma that required a course of steroids for symptomatic oedema within 6 months following SRS/SRT treatment	Of those in the denominator, the number of patients who required a course of steroids within 6 months following SRS/SRT treatment for symptomatic oedema	Total number of patients with meningioma treated with SRS/SRT in the reporting period	Annual	Annual	Provider submitted data	Provider submitted data	N/A	Lower is better	The data required is per delivery site and treatment platform.				Oct 19 - Sep 20
ST10	Domain 2: Enhancing the quality of life of people with long-term conditions	Clinical outcome measure	Skull base tumour control - complications of treatment	This indicator is to measure complications of treatment	Proportion of patients with skull base tumours treated with SRS/SRT with a new or worsened cranial nerve deficit within the 12 months following SRS/SRT treatment	Of those in the denominator, the number of patients with a new or worsened cranial nerve deficit within the 12 months following SRS/SRT treatment	Total number of patients with skull base tumours treated with SRS/SRT in the reporting period	Annual	Annual	Provider submitted data	Provider submitted data	N/A	Lower is better	New or worsened cranial nerve deficits include a change in hearing from serviceable to non-serviceable, new or worsened facial nerve function and numbness. The data required is per delivery site and treatment platform.				Apr 19 - Mar 20
ST11	Domain 2: Enhancing the quality of life of people with long-term conditions	Clinical outcome measure	Complete obliteration of AVM	The purpose of this indicator is to measure the proportion of patients with Arteriovenous Malformations (AVM) where complete obliteration of Arteriovenous Malformations (AVM) has been achieved	Proportion of patients with complete obliteration of Arteriovenous Malformations (AVM) on 3 year angiogram	Of those in the denominator, the number of patients with complete obliteration of AVM on 3 year angiogram	Total number of AVM patients having a 3 year angiogram in the reporting period	Annual	Annual	Provider submitted data	Provider submitted data	N/A	Higher is better	The data required is per delivery site and treatment platform.				Apr 20- Mar 21
ST12a	Domain 2: Enhancing the quality of life of people with long-term conditions.	Clinical Outcome Measure	Pituitary adenoma control	This indicator is to measure the proportion of patients with hormone secreting tumours who have normalisation of hormone levels within 12 months after SRS/SRT treatment. Excessive hormone secretion carries high mortality and morbidity and is expensive to treat by drug therapy and normalisation of levels is the aim of treatment	Proportion of patients with hormone secreting tumours with normalisation within 12 months after SRS/SRT treatment	Of those in the denominator, the number of patients with normalisation within 12 months after SRS/SRT treatment	Total number of patients with hormone secreting tumours treated with SRS/SRT in the reporting period	Annual	Annual	Provider submitted data	Provider submitted data	N/A	Higher is better	Normalisation means to within normal levels, accepted in the definition of cure. The data required is per delivery site and treatment platform.				Apr 19 - Mar 20
ST12b	Domain 2: Enhancing the quality of life of people with long-term conditions	Clinical Outcome Measure	Pituitary adenoma - complications of treatment	Indicator to measure complications of SRS/SRT treatment. This indicator aims to measure the proportion of patients with pituitary adenomas treated with SRS/SRT that have a new visual field deficit and/or cranial nerve deficit within 12 months following the SRS/SRT treatment.	Proportion of patients with a new visual field deficit and/or cranial nerve deficit 12 months post SRS/SRT treatment for pituitary adenomas	Of those in the denominator, the number of patients with a new visual field deficit and/or cranial nerve deficit within the 12 months following SRS/SRT treatment	Total number of patients with pituitary adenomas treated with SRS/SRT in the reporting period	Annual	Annual	Provider submitted data	Provider submitted data	N/A	Lower is better	The data required is per delivery site and treatment platform.				Apr 19 - Mar 20
ST13a	Domain 2: Enhancing the quality of life of people with long-term conditions	Clinical Outcome Measure	Trigeminal neuralgia - facial pain reduction post treatment	Indicator to measure facial pain reduction in patients with trigeminal neuralgia at 1 year post SRS/SRT treatment	Proportion of patients with trigeminal neuralgia reporting a reduction of 1 or more points on the Barrow Neurological Institute Pain Intensity Score at 1 year post SRS/SRT treatment, compared to pre-treatment measurement	Of those in the denominator, the number of patients reporting a reduction of 1 or more points on the Barrow Neurological Institute Pain Intensity Score at 1 year post SRS/SRT treatment compared to pre-treatment measurement	Total number of patients with trigeminal neuralgia treated with SRS/SRT in the reporting period	Annual	Annual	Provider submitted data	Provider submitted data	N/A	Higher is better	The Barrow score is: 0 - no pain no meds, 1 - occasional pain no meds, 2 - some pain but controlled with meds, 3 - some pain not controlled with meds, 4 - Severe pain or no pain relief. The data required is per delivery site and treatment platform.				Apr 19 - Mar 20

Stereotactic Radiosurgery and Stereotactic Radiotherapy - Intracranial (All Ages) Quality Dashboard 2020/21

NHS England

															Reporting Periods			
Indicator Reference Number	Domain	Theme	Measure	Rationale	Name of Indicator / Description	Numerator	Denominator	Period Type	Frequency	Data Source Numerator	Data Source Denominator	Target	Interpretation Guidance	Notes	Q1	Q2	Q3	Q4
ST13b	Domain 2: Enhancing the quality of life of people with long-term conditions	Clinical outcome measure	Trigeminal neuralgia - complications of treatment	A complication of SRS/SRT treatment in patients with trigeminal neuralgia can include anesthesia dolorosa. This indicator measures the proportion of patients with aesthesia dolorosa at 1 year following SRS/SRT treatment	Proportion of patients with anesthesia dolorosa at 1 year following SRS/SRT treatment for trigeminal neuralgia	Of those in the denominator, the number of patients diagnosed with anesthesia dolorosa at 1 year following SRS/SRT treatment	Total number of patients with trigeminal neuralgia treated with SRS/SRT in the reporting period	Annual	Annual	Provider submitted data	Provider submitted data	N/A	Lower is better	The data required is per delivery site and treatment platform.				Apr 19 - Mar 20
ST13c	Domain 2: Enhancing the quality of life of people with long-term conditions	Clinical outcome measure	Trigeminal neuralgia - requirement for other treatments	This indicator is to measure where patients with trigeminal neuralgia have required other interventional or surgical or medical treatment within the 12 months following SRS/SRT treatment	Proportion of patients with trigeminal neuralgia requiring other treatments, within the 12 months following SRS/SRT treatment	Of those in the denominator, the number of patients requiring other treatments within the 12 months following SRS/SRT treatment	Total number of patients with trigeminal neuralgia treated with SRS/SRT in the reporting period	Annual	Annual	Provider submitted data	Provider submitted data	N/A	Lower is better	Other treatments: where other interventional or surgical or medical treatment required. The data required is per delivery site and treatment platform.				Apr 19 - Mar 20
ST14	Domain 2: Enhancing the quality of life of people with long-term conditions	Process measure	Quality of Life (QOL)/Patient Surveys	Quality of Life (QOL)/Patient Surveys to measure quality of life before and after SRS/SRT treatment. This indicator is to provide an initial baseline and aims to establish the proportion of patients treated with SRS/SRT that have been given a Quality of Life (QOL) Patient Survey to complete	Proportion of patients treated with SRS/SRT given a Quality of Life (QOL)/Patient Survey to complete	From the denominator, the number of patients given a Quality of Life (QOL)/ Patient Survey to complete	Total number of patients treated with SRS/SRT in the reporting period	Annual	Annual	Provider submitted data	Provider submitted data	N/A	Neutral	Quality of Life (QOL)/Patient Surveys being given to measure quality of life before and after SRS/SRT treatment. A patient may be given more than one Quality of Life (QOL/ Patient Survey, but must only be counted The data required is per delivery site and treatment platform.				Apr 20 - Mar 21
ST15	Domain 4: Ensuring that people have a positive experience of care	Outcome measure	Recruitment into trials	This indicator can be used to identify and highlight variation in trial recruitment between SRS/SRT service providers	Proportion of patients recruited into SRS/SRT trials (where SRS/SRT is a component of a trial)	Of those in the denominator, the number of patients recruited into trials (where SRS/SRT is a component of the trial)	Total number of patients treated with SRS/SRT in the reporting period	Annual	Annual	Provider submitted data	Provider submitted data	N/A	Higher is better	The data required is per delivery site and treatment platform.				Apr 20 - Mar 21
ST16	Domain 4: Ensuring that people have a positive experience of care	Outcome measure	Complaints	Indicator to measure and monitor complaints	Rate of formal complaints received	Total number of formal complaints received relating to the SRS/SRT service during the reporting period	Total number of patients referred to the SRS/SRT service in the reporting period	Annual	Annual	Provider submitted data	Provider submitted data	N/A	Lower is better	Numerator note: each provider organisation will have a formal complaints process where complaints are logged, registered and tracked. Include any formal complaints received relating to the SRS/SRT service (for any patients referred to the SRS/SRT service). Providers to include all patients referred to the SRS/SRT service and not just patients treated with SRS/SRT. The data required is per delivery site and treatment platform.				Apr 20 - Mar 21
	Data collection has been approved by the Review of Central Returns - ROCR ROCR/OR/2230/001MAND																	